Abstract: The present invention provides a single domain specific binding molecule having the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 in which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.
Type:
Grant
Filed:
May 17, 2021
Date of Patent:
July 4, 2023
Assignee:
ELASMOGEN LIMITED
Inventors:
Caroline Barelle, Mischa Roland Muller, Valerie Calabro, Jack Bikker, John Steven, Lioudmila Tchistiakova, Oleg Kovalenko, Andrea Olland
Abstract: The present invention provides methods for the production of a library of antigen specific antigen binding molecules having a peptide domain structure represented by the following formula (I): FW 1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 comprising (1) isolating RNA from a member of a species in the Elasmobranchii subclass; (2) amplifying DNA sequences from RNA obtained; (3) selecting a DNA sequence from the database prepared; (4) amplifying DNA sequences encoding two or more contiguous peptide domains of FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4; (5) ligating together said amplified DNA sequences to form DNA sequences encoding an antigen specific binding molecule; (6) cloning the amplified DNA obtained into a display vector; and (7) transforming a host with said display vector to produce a library of said antigen specific antigen binding molecules.
Type:
Grant
Filed:
February 11, 2019
Date of Patent:
October 4, 2022
Assignee:
ELASMOGEN LIMITED
Inventors:
Caroline Jane Barelle, William James Jonathan Finlay, Alfredo Darman-In-Sheeman, Andrew Justin Radcliffe Porter
Abstract: The present invention provides a single domain specific binding molecule having the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 in which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.
Type:
Grant
Filed:
March 8, 2019
Date of Patent:
June 15, 2021
Assignee:
ELASMOGEN LIMITED
Inventors:
Caroline Barelle, Mischa Roland Muller, Valarie Calabro, Jack Bikker, John Steven, Lioudmila Tchistiakova, Oleg Kovalenko, Andrea Olland